Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
Abbott (NYSE: ABT) and Genentech, Inc. (NYSE: DNA) have formed acollaboration for the global research, development andcommercialization of two of Abbott’s investigational anti-cancercompounds. The companies will work together on all aspects offurther development and commercialization of ABT-263 and ABT-869,which were discovered by Abbott scientists.
This entry was posted on Tuesday, June 26th, 2007 at 8:49 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.